Integra Tx secures €4.5-million in funding from Advent France Biotechnology, Invivo Capital and Takeda Ventures

by Invivo Capital

Integra Therapeutics (Integra Tx), a biotechnology company that is creating next-generation gene editing tools to boost the efficiency and safety of advanced therapies, has completed its first round o...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Papresa culmina su refinanciación para ...

by Quantum Capital Partners

Papresa ha firmado recientemente su proceso de refinanciación de deud...

Photos Stream